Why the study?
Venous thromboembolism incidence is elevated in patients with malignancy and impacts treatment, prognosis, and mortality, warranting an updated epidemiological review.
Answers are grounded in this paper and cite their sources.
This review provides an update on the epidemiology of cancer-associated venous thromboembolism, highlighting its association with increased mortality and various risk factors.
The incidence of venous thromboembolism (VTE) is known to be higher in patients with malignancy as compared with the general population. It is important to understand and review the epidemiology of VTE in cancer patients because it has implications regarding treatment and prognosis. Multiple studies have shown that cancer patients who develop VTE are at higher risk for mortality. This article will focus on an update regarding the epidemiology of cancer-associated thrombosis (CT). The authors will describe factors associated with CT risk including cancer type and stage at the time of diagnosis, race and ethnicity, and cancer-directed therapy. In addition, recurrent thrombosis and the effect of thromboembolism on survival in cancer patients will also be addressed.
No takes yet. Share an insight, caveat, or question.
Mahajan et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: